Takeda's long-serving chief executive Christophe Weber has said he will retire next year, after 12 years at the Japanese drugmaker. Weber – who was briefly chief operating officer of Takeda ...

Takeda has been restructured under new CEO Christophe Weber, who took over in 2014 and has focused the company on cancer and specialist gastrointestinal drugs, and early stage central nervous ...

Belo, a member of PRWeek’s 2024 Health Influencer list, joined Takeda in 2021 as VP and global head of external communications. The company promoted him to SVP and head of global corporate brand and ...

Takeda has announced that its Board of Directors has approved the appointment of Christophe Weber to become its Chief Operating Officer (COO) and candidate for its next Chief Executive Officer (CEO).

Takeda has announced the appointment of Julie Kim as successor to Christophe Weber, its current president, CEO and representative director, effective from June 2026. The decision was unanimously ...

will succeed CEO Christophe Weber, who plans to step down in June next year. The U.S. is by far the largest market for Takeda, generating about half of the company’s revenue. Founded in 1781 ...

While that may seem mostly symbolic, Takeda, which develops treatments ... Ricci reports directly to CEO Christophe Weber, ...

The Japanese pharma company acquired Ariad a year ago for $5.2bn, and the latest, more modest acquisition, shows that Takeda's chief Christophe Weber sees buy-outs as ongoing route to growth.

Takeda will hold an investor vote on its $62 billion acquisition of Shire next month, and aims to close the deal on January 8. Under the leadership of CEO Christophe Weber, Takeda is hoping to ...

“The Board of Directors has unanimously chosen Julie Kim to lead Takeda into the next chapter, building on the company’s success under Christophe Weber’s remarkable leadership,” said ...